Kelli J. Glenn

发表

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

A. Polonskaia, C. Lukacs, Hongmao Sun, 2013, Bioorganic & medicinal chemistry letters.

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Jing Zhang, Zhuming Zhang, Frank Podlaski, 2013, Journal of medicinal chemistry.

Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans

Kelli J. Glenn, Sazzad Hussain, J. Zhi, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects

Kelli J. Glenn, M. Kamin, L. Vernillet, 2021, Clinical and translational science.

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Binh Vu, L. Vassilev, B. Vu, 2013, ACS medicinal chemistry letters.

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.

L. Vassilev, B. Graves, Z. Filipovic, 2014, Bioorganic & medicinal chemistry.

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis.

Kelli J. Glenn, R. Hoffman, R. Gordon, 2014, Experimental hematology.

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

L. Vassilev, Z. Filipovic, Kelli J. Glenn, 2014, Clinical Cancer Research.

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.

S. So, L. Vassilev, B. Graves, 2014, ACS medicinal chemistry letters.

Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.

Kelli J. Glenn, M. Quinlan, H. Boss, 2016, British journal of clinical pharmacology.

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

D. Carvajal, A. Flohr, Kelli J. Glenn, 2009, Cancer research.

Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate.

Michiko Nakamura, I. Jang, Kelli J. Glenn, 2020, European journal of pharmacology.

Cancer Therapy : Preclinical Preclinical Optimization of MDM 2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

L. Vassilev, Z. Filipovic, Kelli J. Glenn, 2014 .

Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects

Kelli J. Glenn, L. Vernillet, S. Greene, 2020, European Journal of Drug Metabolism and Pharmacokinetics.

Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents

Kelli J. Glenn, Yujin Shin, S. Melnick, 2023, Heliyon.